{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:04:13Z","timestamp":1792260253316,"version":"4.4.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Urinary tract infections, caused primarily by uropathogenic\n                    <jats:italic>E. coli<\/jats:italic>\n                    , are a significant public health burden, affecting approximately 50% of women worldwide. The adhesin FimH is responsible for host receptor binding and is therefore a promising vaccine candidate, but prior studies showed that recombinant monomeric FimH is poorly immunogenic. Here we displayed FimH antigens on the two-component protein nanoparticle I53-50 to generate nanoparticle immunogens that elicit robust levels of receptor-blocking antibodies in mice and non-human primates. We produced nanoparticle immunogens displaying either the FimH lectin domain or a recently reported conformationally stabilized antigen, FimH-DSG, comprising both the lectin and pilin domains. When formulated on aluminum hydroxide, both nanoparticle immunogens elicited similar levels of receptor-blocking activity as a ten-fold higher dose of monomeric FimH-DSG formulated with a potent adjuvant. The improved manufacturability of the stabilized antigen, combined with the ability of nanoparticle display to obviate the need for complex adjuvants, provides important preclinical data for FimH-based vaccines intended to prevent urinary tract infections. More broadly, our data extend the applicability of the I53-50 nanoparticle platform, which to date has been mainly used for displaying viral and protozoan antigens, to bacterial indications.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1872554","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:35:41Z","timestamp":1784612141000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Improving the immunogenicity of E. coli FimH via multivalent display on I53-50 nanoparticles"],"prefix":"10.3389","volume":"17","author":[{"given":"Rebecca S.","family":"Cole","sequence":"first","affiliation":[{"name":"Institute for Protein Design, University of Washington","place":["Seattle, WA, United States"]},{"name":"Department of Biochemistry, University of Washington","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie C.","family":"Silmon de Monerri","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc","place":["Pearl River, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Lypowy","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc","place":["Pearl River, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ponce","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc","place":["Pearl River, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Kobylarz","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc","place":["Pearl River, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Liu","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc","place":["Pearl River, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zein","family":"Kasbo","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc","place":["Pearl River, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Kepl","sequence":"additional","affiliation":[{"name":"Institute for Protein Design, University of Washington","place":["Seattle, WA, United States"]},{"name":"Department of Biochemistry, University of Washington","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Ciolino","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc","place":["Pearl River, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Art","family":"Illenberger","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc","place":["Pearl River, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Gallardo","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc","place":["Pearl River, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalena","family":"Laporte","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc","place":["Pearl River, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Baranova","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc","place":["Pearl River, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Ravichandran","sequence":"additional","affiliation":[{"name":"Institute for Protein Design, University of Washington","place":["Seattle, WA, United States"]},{"name":"Department of Biochemistry, University of Washington","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent O.","family":"Chorro","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc","place":["Pearl River, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.K.","family":"Donald","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc","place":["Pearl River, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Simon","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc","place":["Pearl River, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P.","family":"King","sequence":"additional","affiliation":[{"name":"Institute for Protein Design, University of Washington","place":["Seattle, WA, United States"]},{"name":"Department of Biochemistry, University of Washington","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/b978-0-12-384978-6.00036-4","article-title":"Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden","volume":"28","author":"Foxman","year":"2014","journal-title":"Infect Dis Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.6.2081","article-title":"FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae","volume":"92","author":"Jones","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00169-24","article-title":"A cynomolgus monkey E. coli urinary tract infection model confirms efficacy of new FimH vaccine candidates","volume":"92","author":"Chorro","year":"2024","journal-title":"Infect Immun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1086\/315258","article-title":"Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli","volume":"181","author":"Langermann","year":"2000","journal-title":"J Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5312.607","article-title":"Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination","volume":"276","author":"Langermann","year":"1997","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1834807","article-title":"Safety and immunogenicity of an adjuvanted Escherichia coli adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections: results from a first-in-human phase 1 study","volume":"17","author":"Eldridge","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1359738","article-title":"Case report: Long-term follow-up of patients who received a FimCH vaccine for prevention of recurrent urinary tract infections caused by antibiotic resistant Enterobacteriaceae: a case report series","volume":"15","author":"Perer","year":"2024","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1770034","article-title":"Optimization and qualification of an assay that demonstrates that a FimH vaccine induces functional antibody responses in women with histories of urinary tract infections","volume":"17","author":"Starks","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2010.06.002","article-title":"Donor strand exchange and conformational changes during E. coli fimbrial formation","volume":"172","author":"Le Trong","year":"2010","journal-title":"J Struct Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m117.802942","article-title":"Conformational switch of the bacterial adhesin FimH in the absence of the regulatory domain: Engineering a minimalistic allosteric system","volume":"293","author":"Rabbani","year":"2018","journal-title":"J Biol Chem"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012325","article-title":"Structure-based design of an immunogenic, conformationally stabilized FimH antigen for a urinary tract infection vaccine","volume":"21","author":"Silmon de Monerri","year":"2025","journal-title":"PloS Pathog"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy745","article-title":"New vaccine design and delivery technologies","volume":"219","author":"Kanekiyo","year":"2019","journal-title":"J Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.immuni.2023.08.011","article-title":"Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses","volume":"56","author":"Ols","year":"2023","journal-title":"Immunity"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1578216","article-title":"Immunological basis for enhanced immunity of nanoparticle vaccines","volume":"18","author":"Kelly","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat9120","article-title":"Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers","volume":"363","author":"Tokatlian","year":"2019","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","article-title":"Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus","volume":"176","author":"Marcandalli","year":"2019","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1015840","article-title":"Design and immunological evaluation of two-component protein nanoparticle vaccines for East Coast fever","volume":"13","author":"Lacasta","year":"2022","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.10.043","article-title":"Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B20","article-title":"Adjuvanted COVID-19 vaccine candidate meets coprimary objectives in a phase III study; Biologics License Application submitted for SKYCovione","volume-title":"Skycovione","year":"2022"},{"key":"B21","article-title":"S.Korea approves first domestically developed COVID vaccine","year":"2022","journal-title":"Reuters"},{"key":"B22","doi-asserted-by":"publisher","first-page":"102140","DOI":"10.1101\/2023.01.31.23284895","article-title":"Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial","volume":"64","author":"Song","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.126885","article-title":"Nanoparticles displaying fHbp elicit an enhanced antibody response against meningococcal B isolates compared to low valency fHbp antigens","volume":"51","author":"McKechnie","year":"2025","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf8818","article-title":"Accurate design of megadalton-scale two-component icosahedral protein complexes","volume":"353","author":"Bale","year":"2016","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: Structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen","year":"2021","journal-title":"Protein Sci"},{"key":"B26","unstructured":""},{"key":"B27","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41467-021-21251-y","article-title":"Complete and cooperative in vitro assembly of computationally designed self-assembling protein nanomaterials","volume":"12","author":"Wargacki","year":"2021","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41541-024-00982-1","article-title":"Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens","volume":"9","author":"Miranda","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004857","article-title":"Inhibition and reversal of microbial attachment by an antibody with parasteric activity against the FimH adhesin of uropathogenic E. coli","volume":"11","author":"Kisiela","year":"2015","journal-title":"PloS Pathog"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.710263","article-title":"Stabilization of the SARS-CoV-2 Spike receptor-binding domain using deep mutational scanning and structure-based design","volume":"12","author":"Ellis","year":"2021","journal-title":"Front Immunol"},{"key":"B31","unstructured":""},{"key":"B32","doi-asserted-by":"publisher","first-page":"a031583","DOI":"10.1101\/cshperspect.a031583","article-title":"What is the predictive value of animal models for vaccine efficacy in humans? Consideration of strategies to improve the value of animal models","volume":"10","author":"Herati","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B33","unstructured":""},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100780","article-title":"Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens","volume":"3","author":"Kraft","year":"2022","journal-title":"Cell Rep Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2106845118","article-title":"Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice","volume":"118","author":"Dalvie","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41541-022-00472-2","article-title":"Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice","volume":"7","author":"Grigoryan","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03530-2","article-title":"Adjuvanting a subunit COVID-19 vaccine to induce protective immunity","volume":"594","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.immuni.2022.07.015","article-title":"Vaccination with a structure-based stabilized version of malarial antigen Pfs48\/45 elicits ultra-potent transmission-blocking antibody responses","volume":"55","author":"McLeod","year":"2022","journal-title":"Immunity"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113552","article-title":"Antigen spacing on protein nanoparticles influences antibody responses to vaccination","volume":"42","author":"Ellis","year":"2023","journal-title":"Cell Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1101\/2025.05.11.652904","article-title":"Phylogeny-driven design of broadly protective sarbecovirus receptor-binding domain nanoparticle vaccines","author":"Addetia","year":"2025","journal-title":"bioRxivorg"},{"key":"B41","unstructured":""},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adu2085","article-title":"Computationally designed mRNA-launched protein nanoparticle immunogens elicit protective antibody and T cell responses in mice","volume":"17","author":"Hendricks","year":"2025","journal-title":"Sci Transl Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.01.047","article-title":"Carrier priming or suppression: understanding carrier priming enhancement of anti-polysaccharide antibody response to conjugate vaccines","volume":"32","author":"Pobre","year":"2014","journal-title":"Vaccine"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1586\/erv.11.142","article-title":"Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules","volume":"10","author":"Borrow","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nature12202","article-title":"Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies","volume":"499","author":"Kanekiyo","year":"2013","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.6.1576","article-title":"Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine","volume":"171","author":"Gordon","year":"1995","journal-title":"J Infect Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.03.041","article-title":"Four year immunogenicity of the RTS,S\/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial","volume":"29","author":"Aide","year":"2011","journal-title":"Vaccine"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1084\/jem.180.3.1037","article-title":"Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes","volume":"180","author":"Sch\u00f6del","year":"1994","journal-title":"J Exp Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/0168-1656(95)00118-2","article-title":"Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes","volume":"44","author":"Sch\u00f6del","year":"1996","journal-title":"J Biotechnol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007611","article-title":"A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon","volume":"4","author":"Lell","year":"2009","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.csbj.2015.11.001","article-title":"Self-assembling protein nanoparticles in the design of vaccines","volume":"14","author":"L\u00f3pez-Sagaseta","year":"2016","journal-title":"Comput Struct Biotechnol J"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115036","article-title":"Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV","volume":"43","author":"Chao","year":"2024","journal-title":"Cell Rep"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2020.01.007","article-title":"Shaping humoral immunity to vaccines through antigen-displaying nanoparticles","volume":"65","author":"Irvine","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.03.001","article-title":"An assessment of the use of Hepatitis B Virus core protein virus-like particles to display heterologous antigens from Neisseria meningitidis","volume":"38","author":"Aston-Deaville","year":"2020","journal-title":"Vaccine"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0273322","article-title":"Self-assembling protein nanoparticles and virus like particles correctly display \u03b2-barrel from meningococcal factor H-binding protein through genetic fusion","volume":"17","author":"Cappelli","year":"2022","journal-title":"PloS One"},{"key":"B56","article-title":"Protein identification and analysis tools in the ExPASy server","volume-title":"2-D Proteome Analysis Protocols","author":"Wilkins","year":"2003"},{"key":"B57","article-title":"Compositions and methods for treatment and prevention of uropathogenic e. coli infection","author":"Sokurenko","year":"2018"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1872554\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:35:42Z","timestamp":1784612142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1872554\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2026.1872554"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1872554","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1872554"}}